

Financial Supervision Authority

Current report No. 36/2018

Date prepared: 01/06/2018

Abbreviated name of the issuer:

Mabion S.A.

Subject:

The application for approval of MabionCD20 to the European Medicines Agency.

Legal basis

Art. 17. par. 1 MAR – inside information.

Content of the report:

In reference to Current Report No. 13/2018 of 23 March 2018, the Management Board of Mabion S.A. (“Company”) informs that on June 1, 2018 the Company submitted an application to the European Medicines Agency (EMA) for marketing authorization (MAA) for a drug with a working name “MabionCD20”.

The Company informs that the positive results of the study, considered in the above report, does not guarantee product approval by the European Medicines Agency.